Clinical Profiling of BCL-2 Family Members in the Setting of BRAF Inhibition Offers a Rationale for Targeting De Novo Resistance Using BH3 Mimetics

While response rates to BRAF inhibitiors (BRAFi) are high, disease progression emerges quickly. One strategy to delay the onset of resistance is to target anti-apoptotic proteins such as BCL-2, known to be associated with a poor prognosis. We analyzed BCL-2 family member expression levels of 34 samp...

Descripción completa

Detalles Bibliográficos
Autores principales: Frederick, Dennie T., Salas Fragomeni, Roberto A., Schalck, Aislyn, Ferreiro-Neira, Isabel, Hoff, Taylor, Cooper, Zachary A., Haq, Rizwan, Panka, David J., Kwong, Lawrence N., Davies, Michael A., Cusack, James C., Flaherty, Keith T., Fisher, David E., Mier, James W., Wargo, Jennifer A., Sullivan, Ryan J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4077767/
https://www.ncbi.nlm.nih.gov/pubmed/24983357
http://dx.doi.org/10.1371/journal.pone.0101286

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4077767/
https://www.ncbi.nlm.nih.gov/pubmed/24983357
http://dx.doi.org/10.1371/journal.pone.0101286

Ejemplares similares